Medicare Enrolled

Dr. Keshav Narain, M.D.

Retina Specialist (Ophthalmology) Physician · San Jose, CA
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
455 OCONNOR DR, San Jose, CA 95128
4082943534
In practice since 2006 (19 years)
NPI: 1487680328 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Narain from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Narain? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Narain

Dr. Keshav Narain is a retina specialist physician in San Jose, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Narain performed 7,520 Medicare services across 2,885 unique beneficiaries.

Between the years covered by Open Payments, Dr. Narain received a total of $14,455 from 38 pharmaceutical and/or device companies across 281 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in retina specialist (ophthalmology) physician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Narain is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 37% volume in CA $14,455 industry payments

Medicare Practice Summary

Medicare Utilization ↗
7,520
Medicare services
Top 37% in CA for retina specialist (ophthalmology) physician
2,885
Unique beneficiaries
$76
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~396 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Eye injection (Vabysmo/faricimab)
An injection of faricimab-svoa, a medication administered in 0.1 mg doses.
2,700 $29 $149
Comprehensive eye exam, established patient
A comprehensive examination of the visual system performed for a patient who has previously been seen by the provider.
755 $117 $350
Retinal and optic nerve function test
A diagnostic test that measures how well the retina and optic nerve are functioning.
582 $130 $350
Visual evoked potential test
A test that measures how quickly electrical signals travel from the eye to the brain in response to visual stimuli.
578 $72 $350
Retinal imaging (OCT scan)
This procedure involves imaging the retina to visualize its structure. It is used to examine the back of the eye.
441 $39 $150
Retinal photography (fundus photo)
This procedure involves taking photographs of the retina, the light-sensitive tissue at the back of the eye. It is used to document the condition of the eye's interior structures.
421 $35 $250
Optic nerve imaging (OCT scan)
Imaging of the optic nerve.
379 $34 $150
Visual field test, extended
A test that maps your complete field of vision to detect blind spots or peripheral vision loss. Extended testing provides a more detailed assessment than a standard visual field exam.
365 $58 $200
Laser repair to improve eye fluid flow
A laser procedure used to enhance the drainage of fluid within the eye.
265 $228 $1,046
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
249 $114 $300
Office visit, established patient (10-19 min)
An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition.
234 $47 $120
Eye injection for retinal disease
A procedure involving the administration of medication directly into the eye.
161 $109 $629
Aflibercept eye injection (Eylea) 114 $697 $3,000
Imaging of front third of eye
Imaging of the front third of the eye.
70 $29 $110
Comprehensive eye exam, new patient
A comprehensive examination of the visual system performed for a new patient.
66 $127 $375
Retinal angiography with dye injection
This procedure uses a special camera to examine the blood vessels in the retina after a dye has been injected into the body.
51 $148 $300
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
45 $83 $180
Bevacizumab injection, 10 mg
Administration of a 10 mg dose of bevacizumab medication via injection.
30 $57 $150
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
14 $133 $388
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$14,455
Total received (2018-2024)
Avg $2,065/year across 7 years
Top 12% in CA for retina specialist (ophthalmology) physician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
38
Companies
281
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$8,410 (58.2%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$5,625 (38.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$419 (2.9%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$2,462
2023
$1,605
2022
$1,943
2021
$709
2020
$308
2019
$525
2018
$6,903

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
BIOTISSUE HOLDINGS INC.
$846
Amgen Inc.
$666
Tarsus Pharmaceuticals, Inc.
$217
Apellis Pharmaceuticals, Inc.
$203
Bausch & Lomb Americas Inc.
$200
Oyster Point Pharma, Inc.
$97
SUN PHARMACEUTICAL INDUSTRIES INC.
$78
Astellas Pharma US Inc
$53
Regeneron Healthcare Solutions, Inc.
$38
Alcon Vision LLC
$38
Harrow Eye, LLC
$25
Top 3 companies account for 70.2% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$3,261
Cardinal Health 108, LLC
$2,707
BioTissue Holdings, Inc.
$898
BIOTISSUE HOLDINGS INC.
$846
Sun Pharmaceutical Industries Inc.
$719
Amgen Inc.
$666
Oyster Point Pharma, Inc.
$589
Horizon Therapeutics plc
$519
Allergan Inc.
$485
Bausch & Lomb Americas Inc.
$400
Kala Pharmaceuticals, Inc.
$289
Shire North American Group Inc
$286
Apellis Pharmaceuticals, Inc.
$255
Tarsus Pharmaceuticals, Inc.
$217
Astellas Pharma US Inc
$196
Allergan, Inc.
$188
Bausch & Lomb, a division of Bausch Health US, LLC
$187
TISSUETECH, INC.
$175
Notal Vision, Inc.
$173
Alimera Sciences, Inc.
$166
SUN PHARMACEUTICAL INDUSTRIES INC.
$163
Carl Zeiss Meditec, Inc.
$148
Regeneron Healthcare Solutions, Inc.
$131
Alcon Vision LLC
$127
Alcon Laboratories Inc
$125
Carl Zeiss Meditec USA, Inc.
$124
Eyevance Pharmaceuticals LLC
$75
E.R. Squibb & Sons, L.L.C.
$55
Thea Pharma Inc.
$49
BIOTISSUE HOLDINGS, INC.
$47
EyePoint Pharmaceuticals US, Inc.
$35
Harrow Eye, LLC
$25
Genentech USA, Inc.
$25
ABBVIE INC.
$23
Spark Therapeutics, Inc.
$22
EYEVANCE PHARMACEUTICALS LLC
$20
ABIOMED
$20
VYERA PHARMACEUTICALS, LLC
$17
Top 3 companies account for 47.5% of all-time payments
Associated products mentioned in payments ›
BROLUCIZUMAB · BROMSITE · CEQUA · CIRRUS HD-OCT · COMBIGAN · Cequa · CyPass · DUREZOL · DURYSTA · Daraprim · ELIQUIS · EYLEA · EYLEA AFLIBERCEPT INJECTION · EYLEA HD · EYSUVIS · Flarex · INVELTYS · Iluvien · Impella · Izervay · LOTEMAX SM · LUMIGAN · LUXTURNA · MIEBO · PROKERA · PROLENSA · RESTASIS · RESTASIS MULTIDOSE · Rocklatan · Simbrinza · Syfovre · TEPEZZA · TRAVATAN Z · TYRVAYA · Tobradex ST · VEVYE · VUITY · VYZULTA · Vabysmo · VisuMax · XDEMVY · XELPROS · XIIDRA · YUTIQ · Zerviate
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (58%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a retina specialist physician in San Jose?
Compare retina specialist physicians in the San Jose area by procedure volume, costs, and industry payment transparency.
Browse retina specialist physicians nearby

Geographic Context

Retina specialist physicians within 10 mi
9
Per 100K population
0.5
County median income
$159,674
Nearest hospital
SANTA CLARA VALLEY MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Narain is a mixed practice specialist, with moderate Medicare volume, with low-engagement industry engagement in the top 12% of CA peers, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Narain experienced with eye injection (vabysmo/faricimab)?
Based on Medicare claims data, Dr. Narain performed 2,700 eye injection (vabysmo/faricimab) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Narain receive payments from pharmaceutical companies?
Yes. Dr. Narain received a total of $14,455 from 38 companies across 281 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Narain's costs compare to other retina specialist physicians in San Jose?
Dr. Narain's average Medicare payment per service is $76. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Narain) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →